FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

证券时报•数据宝统计显示，1月13日有39家香港上市公司进行了股份回购，合计回购1751.51万股，回 购金额8.96亿港元。 腾讯控股回购数量101.20万股，回购金额6.36亿港元，回购最高价为638.000港元，最低价为623.000港 元，年内累计回购金额50.86亿港元；小米集团-W回购数量400.00万股，回购金额1.52亿港元，回购最 高价为38.040港元，最低价为37.940港元，年内累计回购金额9.42亿港元；舜宇光学科技回购数量64.00 万股，回购金额4178.78万港元，回购最高价为65.800港元，最低价为64.550港元，年内累计回购金额 2.29亿港元。 以金额进行统计，1月13日回购金额最多的是腾讯控股，回购金额为6.36亿港元；其次是小米集团-W， 回购金额为1.52亿港元；回购金额居前的还有舜宇光学科技、巨子生物等。回购数量上看，1月13日回 购股数最多的是小米集团-W，当日回购量为400.00万股；其次是捷利交易宝、碧桂园服务等，回购数 量分别为180.80万股、139.40万股。（数据宝） 1月13日港股公司回购一览 （万股） 回购金额 （万港元） 回购最高价 （港元 ...

Group 1 - The article discusses the share buybacks conducted by various companies on January 13, 2026, with Tencent Holdings (00700) having the largest buyback amount of 636 million yuan for 1.012 million shares [1][2] - Other notable companies involved in the buyback include Xiaomi Group (01810) with 4 million shares repurchased for 152 million yuan, and Sunny Optical Technology (02382) with 640,000 shares for approximately 41.79 million yuan [1][2] - The total number of shares repurchased by Tencent Holdings in the year reached 11 million, representing 1.199% of its total share capital [2] Group 2 - The buyback activities reflect a strategic move by companies to enhance shareholder value and signal confidence in their financial health [1][2] - Companies like Weigao Group (01066) and Xinli International (00732) also showed significant buyback activity, with Weigao repurchasing 27,440 shares for 1.4962 million yuan, representing 6.519% of its total share capital [2] - The data indicates a trend among companies to engage in share buybacks as a method to return capital to shareholders and potentially boost stock prices [1][2][3]

Investment Rating - The report initiates coverage with an OUTPERFORM rating for Giant Biogene, with a target price of HK$43.60, indicating a potential upside of 22.0% from the current price of HK$35.74 [1][2][7]. Core Insights - The report expresses a long-term positive outlook on the recombinant collagen sector, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry growth [4][34]. - Giant Biogene has established itself as a leader in the recombinant collagen market, with a strategic shift towards brand development in 2026 [9][30]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are estimated at RMB 54.9 billion, RMB 59.9 billion, and RMB 66.9 billion, respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [7][32]. - Net profit forecasts for the same years are RMB 18.8 billion, RMB 20.0 billion, and RMB 22.1 billion, with growth rates of -9.0%, 6.6%, and 10.5% [7][32]. - The gross profit margin is expected to remain stable at approximately 80.5% in 2025, declining slightly to 79.2% by 2027 [7][32]. Brand and Product Strategy - Giant Biogene operates eight brands, with the core brands being Kefu Mei and Keli Jin, which contribute over 95% of the company's revenue [5][11][13]. - The company plans to launch a medical device and five skincare series in 2026, alongside a brand revamp for Keli Jin [6][30][31]. - The focus will be on expanding both online and offline channels, with plans to increase the number of physical stores and enhance partnerships with high-potential retailers [31][32]. Market Position and Challenges - The company faces short-term challenges due to discussions around the content and testing methods of recombinant collagen, which have impacted sales, particularly for the Kefu Mei brand [18][20][25]. - Despite these challenges, the company is adjusting its strategies, including enhancing online marketing and product offerings to stabilize and grow its market presence [25][29][30].

巨子生物(02367.HK)1月13日耗资1433.8万港元回购40万股 巨子生物(02367.HK)1月12日耗资1400万港元 回购40万股 相关事件 格隆汇1月13日丨巨子生物(02367.HK)公告，1月13日耗资1433.8万港元回购40万股，每股回购价35.64- 36.2港元。 ...

巨子生物(02367)发布公告，于2026年1月13日斥资1433.78万港元回购40万股。 ...

智通财经APP讯，巨子生物(02367)发布公告，于2026年1月13日斥资1433.78万港元回购40万股。 ...

第 1 頁 共 8 頁 v 1.3.0 | 1). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.941 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年12月9日 | | | | | | 2). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.956 | | | 變動日期 | 2025年12月10日 | | | | | | 3). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 34.7189 | | | 變動日期 | 2025年12月11日 | | | | | | 4). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.0909 | | | 變動日期 | 2025年12月12日 | | | | | | 5). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 34.7931 | | | 變動日期 ...

Group 1 - The article reports on share buybacks conducted by various companies on January 12, 2026, with Tencent Holdings (00700) having the largest buyback amount of 636 million yuan for 1.024 million shares [1][2] - Other notable companies involved in the buyback include Geely Automobile (00175) with 9.007 million shares repurchased for 151 million yuan, and Sunny Optical Technology (02382) with 1.24 million shares for 79.34 million yuan [1][2] - The total number of shares repurchased by Tencent represents 1.188% of its total share capital, while Geely's buyback accounts for 0.438% of its total share capital [2] Group 2 - The buyback activities reflect a trend among companies to return capital to shareholders, with some companies like Antong Oilfield Services (03337) and Weigao Group (01066) showing significant percentages of their total share capital being repurchased, at 2.460% and 6.459% respectively [2][3] - Companies such as Vitasoy International (00345) and Keep (03650) also participated in the buyback, with their repurchase amounts being 432,600 yuan and 28,900 yuan respectively, indicating a diverse range of companies engaging in this practice [3] - The data suggests a strategic move by these companies to enhance shareholder value and potentially stabilize their stock prices amid market fluctuations [1][2]

巨子生物(02367)发布公告，于2026年1月12日，该公司斥资1400.29万港元回购40万股股份，每股回购价 格为34.5-35.5港元。 ...